MIMegumi Ishiguro

Megumi Ishiguro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Megumi Ishiguro has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A phase II study of panitumumab with FOLFOX or FOLFIRI as first-line chemotherapy for KRAS-wild type metastatic colorectal cancer: The PaFF-J study.

    by Eiji Shinozaki, Megumi Ishiguro, Eiji Nakatani, Tatsuro Yamaguchi, Masato Nakamura, Yuji Miyamoto, Hitoshi Ojima, Yoshitaka Honma, Masahiro Gotoh, Toshiaki Ishikawa, et al.

    722 Background: For the patients with unresectable metastatic colorectal cancer (mCRC), response to the1st line chemotherapy has strong impact on their prognosis. Shrinkage of tumors may result in conversion to surgical resection and, concurrently, improved their survival. We conducted a multicenter phase II trial to investigate the efficacy and safety of panitumumab (Pmab) with chemotherapy as the 1st line treatment in Japanese patients with mCRC. Methods: Patients with no prior chemotherapy for unresectable, KRAS wild type mCRC, 20-80 years, and PS 0-1 were arbitrarily received either FOLFOX + Pmab or FOLFIRI + Pmab. Patients were evaluated every 8 weeks until progression. The primary endpoint was overall response rate (ORR), the secondary endpoints were progression-free survival (PFS), overall survival (OS), disease control rate (DCR), R0 resection rate, and safety. Results: A total of 162 patients (140 with FOLFOX + Pmab and 22 with FOLFIRI + Pmab) were analyzed. Median follow-up was 28.2 months, median age at enrollment was 64.5 years, and 17.9% of the patients was recurrent disease. Number of target organ was 1 in 35.2%, 2 in 40.7%, and ≥ 3 in 24.1% of the subjects. Median administered cycle was 7, and median treatment duration was 16 weeks. ORR was 51.2% (95%CI: 43.3-59.2), and DCR was 82.1% (95%CI: 75.3-87.7). ≥ 30% tumor shrinkage (PR-in) was observed in 115 patients (71.0%). Median time to PR-in and maximum shrinkage was 10 and 16 weeks, respectively. Surgical resection was done in 66 patients (40.7%), of which R0 was in 43 patients; R0 resection rate was 26.5% (95%CI: 19.9-34.0). Median PFS and OS was 9.2 (95%CI: 7.2-11.4) and 33.8 months (95%CI: 29.4-43.1), respectively. ≥ Grade 3 adverse events with > 5% incidence were neutropenia (31.8%), stomatitis (10.5%), rash acneiform (9.9%), paronychia (9.3%), anorexia (8.6%), and diarrhea (6.2%). Conclusions: In our study, OS was favorable with high R0 resection rate, whereas ORR, DCR, PFS and toxicities were similar to those in previously reported studies. Because the maximum tumor shrinkage was observed around 16 weeks, optimal timing for considering conversion surgery might be 16 weeks from the start of treatment. Clinical trial information: UMIN000004991.


  • A randomized phase III trial of 1-year adjuvant chemotherapy with oral tegafur-uracil (UFT) vs. surgery alone in stage II colon cancer: SACURA trial.

    by Yoshiki Kajiwara, Megumi Ishiguro, Satoshi Teramukai, Chu Matsuda, Shoichi Fujii, Yusuke Kinugasa, Yoshihiko Nakamoto, Masanori Kotake, Yoshiyuki Sakamoto, Kiyotaka Kurachi, et al.

    3617 Background: Efficacy of adjuvant chemotherapy in stage II colon cancer patients is still controversial. The SACURA trial is a phase III study to evaluate the superiority of 1-year adjuvant treatment with oral tegafur-uracil (UFT) to surgery alone for stage II colon cancer in a large population. Methods: 20-80 aged patients with curatively resected stage II colon cancer were randomly assigned to the surgery alone group or UFT group (UFT at 500-600 mg/day as tegafur in 2 divided doses for 5 days, followed by 2-day rest, then repeated for 1 year). Primary endpoint was disease-free survival (DFS), and the secondary endpoints were overall survival (OS), recurrence-free survival (RFS), and safety. Sample size was 2000 determined with an assumed hazard ratio (HR) 0.729, respectively, a two-sided significance level of 5%, and a power of 90%. Results: A total of 1982 patients (997 in the surgery alone group and 985 in the UFT group) were included in the efficacy analysis. Median follow-up was 69.5 months, the median age at enrollment was 66 years, and stage IIA/IIB/IIC were 84%/13%/3%, respectively. The 5-year DFS rate was 78.4% in the surgery alone group and 80.2% in the UFT group. The HR for DFS was 0.91 (95%CI, 0.75-1.10; p = 0.307), and superiority of the UFT group was not demonstrated. Approximately 9% of patients in the both groups experienced second cancers, which consist 41.7% of the DFS events. The 5-year RFS rate was 84.6% and 87.2% (HR, 0.82; 95%CI, 0.65-1.04), and the 5-year OS rate was 94.3% and 94.5% (HR, 0.93; 95%CI, 0.66-1.31) in the surgery alone group and the UFT group, respectively. The completion rate of the 1-year UFT was 60.8%. The Incidence of grade 3/4 adverse events in the UFT group was 3.7% for ALT elevation, 3.3% for AST elevation, 1.4% for hyperbilirubinemia, 2.6% for anorexia, 1.9% for nausea, 1.4% for diarrhea, and < 1% for hematologic toxicities. Conclusions: Superiority of 1-year adjuvant treatment with UFT to surgery alone was not demonstrated in patients with stage II colon cancer. Clinical trial information: NCT00392899.


  • Planned safety analysis of the ACTS-CC 02 trial: A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/LV as adjuvant chemotherapy for high-risk stage III colon cancer.

    by Takuya Miura, Eiji Sunami, Tetsuya Kusumoto, Mitsuyoshi Ota, Kazuhiro Yoshida, Naohiro Tomita, Atsuyuki Maeda, Izumi Mochizuki, Michio Okabe, Katsuyuki Kunieda, et al.

    3622 Background: The ACTS-CC 02 trial was designed to verify the superiority of postoperative adjuvant chemotherapy with S-1/oxaliplatin (SOX) over Japanese standard treatment with UFT/LV in terms of disease-free survival in patients (pts) with high-risk stage III colon cancer. To date, no phase III trials evaluating SOX as postoperative adjuvant chemotherapy have been reported. We report the results of a planned safety analysis. Methods: Pts who underwent curative resection for high-risk stage III colon cancer were randomly assigned to either UFT/LV (300–600 mg/day of UFT according to body surface area [BSA] and 75 mg/day of LV on days 1-28, every 35 days, 5 courses) or SOX (100 mg/m2 of oxaliplatin on day 1 and 80–120 mg/day of S-1 according to BSA on days 1-14, every 21 days, 8 courses). The dose and adverse events (AEs) in each course were recorded. Results: From April 2010 through October 2014, a total of 966 pts were enrolled at 260 institutions. The safety analysis set (derived by excluding pts who received no protocol treatment from the full analysis set which excluded pts who withdrew informed consent) comprised 472 pts in UFT/LV and 460 in SOX. The median age was 65.0 years, with men accounting for 54.2%, an ECOG PS of 0 in 94.2%, and colon + rectosigmoid cancer in 86.4%.Demographic factors were well balanced. The population of pts who received the planned 6-month protocol treatment was 76.9% in UFT/LV and 65.8% in SOX. The overall incidences of any grade AEs in UFT/LV and SOX were 91.3% and 98.7%, respectively. The incidences of grade ≥ 3 AEs were 15.9% and 35.7% respectively, including neutropenia (1.5% v 17.2%), thrombocytopenia (0.6% v 2.8%), increased AST (2.1% v 0.7%), increased ALT (3.0% v 0.9%), anorexia (2.3% v 3.5%), nausea (0.8% v 2.0%), diarrhea (8.1% v 5.4%), fatigue (1.1% v 1.5%) and sensory neuropathy (0.2% v 4.6%). There was 1 treatment-related death (fulminant hepatitis) in UFT/LV. Conclusions: The incidence of AEs associated with SOX as postoperative adjuvant chemotherapy for colon cancer was considered acceptable, although slightly higher than that of UFT/LV. It was similar to that reported for adjuvant chemotherapy with FOLFOX or CapeOX. Clinical trial information: JapicCTI-101073.


    • 1 March 2016
      • Vol. 36  (3) , 853-60

    Genome-wide DNA Copy-number Analysis in ACTS-CC Trial of Adjuvant Chemotherapy for Stage III Colonic Cancer.

    by Toshiaki Ishikawa, Hiroyuki Uetake, Kenta Murotani, Takashi Kobunai, Megumi Ishiguro, Shigeyuki Matsui, Kenichi Sugihara

    The adjuvant chemotherapy trial of TS-1 for colon cancer phase III trial was designed to validate the non-inferiority of the oral fluoropyrimidine S-1 to uracil and tegafur/leucovorin as adjuvant chemotherapy for stage III colonic cancer. As a prospective biomarker study of this trial, DNA copy number was studied using formalin-fixed, paraffin-embedded specimens. FFPE blocks were obtained from 795 patients of the 1,535 patients enrolled in the study. The quality of extracted DNA was assessed using arbitrarily primed polymerase chain reaction and microfluidic analysis. Genomic copy-number alterations in cancer were analyzed by high-density single-nucleotide polymorphism arrays. Copy-number changes in Japanese patients with colonic cancer were compared with those in Western countries using data from a previously reported meta-analysis. We then compared genome-wide segment copy number and clinicopathological features of colorectal cancer. Genome-wide copy number was analyzed in 161 samples and DNA copy-number alteration profiles showed frequent DNA copy-number gains at chromosome 7, 8q and 13, and losses at 4, 5q, 8p, 17p and 18q. The weighted kappa statistic from comparing copy-number alteration status with data from Western countries was 0.828 (95% confidence interval=0.786 -0.871). DNA copy-number alterations of 8,684 segments were compared with clinicopathological features in 161 patients. Location of the tumor correlated with genomic segments of chromosome 4, 5, 7, 8, 13, 14, 18 and 20. Differentiation of the tumor correlated with segments in chromosome 4, 6, 8, 11, 13, 14,15, 16, 17 and 20. Somatic copy-number alteration profiles of stage III colonic cancer in the Japanese ACTS-CC trial closely agreed with the results of previous Western studies. Location and differentiation of the tumor correlated with DNA copy-number alterations. Our findings will facilitate understanding the characteristics of colonic cancer. Further investigation may contribute to the exploration of valid biomarkers.


  • A multicenter phase II trial of mFOLFOX6 plus bevacizumab as treatment for liver-only metastases from colorectal cancer unsuitable for upfront resection (TRICC0808): Final analysis for survival.

    by Hiroshi Tamagawa, Hiroyuki Uetake, Megumi Ishiguro, Nobuyuki Mizunuma, Yusuke Kinugasa, Izumi Mochizuki, Tetsuya Hamaguchi, Junichi Hasegawa, Kenji Katsumata, Keiichiro Ishibashi, et al.

    704 Background: TRICC0808 trial is a phase II trial to evaluate the liver resection rate and safety after mFOLFOX6 + bevacizumab therapy for liver-only metastasis that is unsuitable for upfront resection (H2 and H3) from colorectal cancer. Primary endpoint was the R0 resection rate, which was reported to be 44.4% (Ann Surg Oncol 22: 908-915, 2015). Final analysis of TRICC0808 was performed (February 16, 2015 data fixation). Methods: Forty six patients were registered and OS was analyzed for 45 patients (FAS). In 24 cases with liver resection after protocol chemotherapy, RFS, recurrence rate and recurrence patterns were analyzed. Results: The1, 2 and 3 year OS rate in FAS from the starting date of the chemotherapy was 91.1%, 68.9%, 44.0%, respectively, with 2.80 years of MST. The 3 year OS rate in 31 patients with liver resection including resection after additional chemotherapy was 61.3% with 3.59 years of MST, which was better than 0% of the 3 year OS rate with 1.75 years of MST in patients without liver resection. In 24 who underwent liver resection after 6 cycles of protocol chemotherapy, the 1, 2 and 3 year RFS rate was 29.2%, 12.5%, 8.3%, respectively, with 3.07 years of MST. The recurrence rate for 20 patients with R0 liver resection was 80%, and 100% in those with R1 and R2 liver resection. In the 20 patients with R0 liver resection, the 3 year OS rate of 16 patients with technically resectable liver metastasis at registration and 4 with technically unresectable tumors was 53.6% and 50.0%, respectively. Conclusions: The present final analysis of TRICC0808 trial disclosed good OS in the patients with liver resection, though the large population of the patients recurred afterward. The results were concordant with those of other reported trials for liver metastasis which is unsuitable for upfront resection. Liver resection was thought to be effective for liver metastasis which converted from unresectable to resectable after chemotherapy. Clinical trial information: UMIN000010209.

    • 1 February 2016
      • Vol. 43  (2) , 156-9

    [Adjuvant Chemotherapy for Colorectal Cancer].

    by Shinichi Yamauchi, Hiroyuki Uetake, Toshiaki Ishikawa, Megumi Ishiguro, Masamichi Yasuno

    The purpose of adjuvant chemotherapy for patients with colorectal cancer treated with curative surgery is to prevent from metachronous recurrences and to improve their prognosis. Because surgical outcomes in Japan are relatively better compared to those in western countries, optimal and personalized treatment based on evidence introduced not only by other countries but by Japan should be chosen. We now focus on a research of identification of biomarker which predict high risk of recurrence in Stage II colorectal cancer.

    • 1 November 2014
      • Vol. 41  (12) , 1701-3

    [A case of postoperative colon cancer with peritoneal dissemination in which a long-term response was achieved using panitumumab maintenance therapy].

    by Hidenori Takahashi, Toshiaki Ishikawa, Noriko Iwata, Hironobu Baba, Yasunori Someno, Satoshi Okazaki, Takatoshi Matsuyama, Megumi Ishiguro, Hirotoshi Kobayashi, Satoru Iida, et al.

    A 66-year-old man underwent a sigmoidectomy for advanced sigmoid colon cancer. The pathological examination revealed that the tumor was T3, N0, M0, and KRAS wild type. Fifteen months after surgery, the patient was hospitalized with stenosis of the anastomosis due to recurrent disease that had disseminated to the peritoneum, and which was unresectable. After transverse colostomy, the patient received 8 courses of mFOLFOX6+panitumumab (Pmab), and 39 courses of infusional 5-fluorouracil (5-FU) + Leucovorin (LV)+ Pmab. A partial remission (PR) was maintained for 27 months. The utility of maintenance therapy with an anti-epidermal growth factor receptor (EGFR) antibody-based regime has not previously been demonstrated. In this case, a long PR was achieved using infusional 5-FU+LV+Pmab, suggesting that this is a useful maintenance therapy following mFOLFOX6 + Pmab. However, the side effects resulting from Pmab treatment reduced the patient's quality of life (QOL). We suggest that Pmab maintenance therapy can be established by controlling the side effects of the anti-EGFR antibody.


    • 1 November 2014
      • Vol. 41  (12) , 1855-7

    [Three cases of anal squamous cell carcinoma treated with chemoradiotherapy].

    by Yasunori Someno, Toshiaki Ishikawa, Noriko Iwata, Hidenori Takahashi, Akifumi Kikuchi, Satoshi Okazaki, Megumi Ishiguro, Hirotoshi Kobayashi, Satoru Iida, Hiroyuki Uetake, et al.

    We reviewed the clinical records of 3 patients with anal squamous cell carcinoma treated with chemoradiotherapy (CRT). Case 1: The patient was diagnosed with StageI (T1N0M0) and treated with cisplatin (CDDP)+5-FU+radiation. Chemotherapy was discontinued after the second course because of adverse effects. She achieved partial response(PR), and underwent a salvage surgery. Seven months after the surgery, she died from other comorbidities. Case 2: The patient was diagnosed with Stage I (T1N0M0) and treated with CDDP+5-FU+radiation. Chemotherapy was discontinued after the second course because of adverse effects. He achieved PR, and underwent a salvage surgery. Three years and 7 months after the surgery, he died from other comorbidities. Case 3: The patient was diagnosed with Stage IIIB (T4N1M0) and treated with MMC+S-1+radiation. Chemotherapy was discontinued after the first course because of adverse effects. She achieved complete response (CR) and is still surviving without cancer recurrence. We conclude that CRT is an effective treatment for anal squamous cell carcinoma.

    • 1 January 2014
      • Vol. 72  (1) , 143-9

    [Diagnosis and management of hereditary colorectal cancer according to the JSCCR Guidelines 2012 for the Clinical Practice of Hereditary Colorectal Cancer].

    by Hideyuki Ishida, Takeo Iwama, Naohiro Tomita, Kouichi Koizumi, Kiwamu Akagi, Megumi Ishiguro, Toshiaki Watanabe, Kenichi Sugihara

    We summarized the key points of the diagnosis and management of familial adenomatous polyposis (FAP) and Lynch syndrome (LS) according to the JSCCR Guidelines 2012 for the Clinical Practice of Hereditary Colorectal Cancer. The diagnosis of FAP is made clinically and/or genetically. A total proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the standard treatment for preventing the development of colorectal cancer, while a total colectomy with ileo-rectal anastomosis (IRA) is an alternative option in select patients. Surveillance for the remnant (colo) rectal mucosa and extra-colonic manifestations, such as the desmoid tumors or duodenal polyposis, is important. Meanwhile, genetic testing is essential for the diagnosis of LS. The genetic testing for mismatch repair gene (s) (MLH1, MSH2, MSH6, and PMS2) is performed using a microsatellite instability test or immunohistochemistry for the 4 kinds of mismatch repair proteins in colorectal cancer tissue from patients who meet the Amsterdam criteria or the revised Bethesda guidelines. Surveillance for metachronous colorectal cancer and extracolonic neoplasms is mandatory in LS patients undergoing surgery for initially diagnosed colorectal cancer.


    • 1 November 2013
      • Vol. 40  (12) , 1915-7

    [Resection for the treatment of bleeding caused by ovarian metastasis after hepatectomy for metachronous liver metastasis from sigmoid colon cancer].

    by Hirotoshi Kobayashi, Hiroyuki Uetake, Satoru Iida, Toshiaki Ishikawa, Megumi Ishiguro, Satoshi Okazaki, Akifumi Kikuchi, Hironobu Baba, Hidenori Takahashi, Noriko Iwata, et al.

    We describe the case of a 75-year-old woman who underwent bilateral oophorectomy for bleeding due to right ovarian metastasis after hepatectomy for metachronous liver metastasis from sigmoid colon cancer. She underwent curative resection for sigmoid colon cancer( T4a, N2, M0, Stage IIIC). She received adjuvant chemotherapy of tegafur/uracil(UFT) plus leucovorin for 6 months. The patient underwent hepatectomy for liver metastasis 13 months after the primary resection for sigmoid colon cancer. One year after liver resection, the patient underwent emergency surgery for the treatment of bleeding due to ovarian metastasis. She received adjuvant capecitabine chemotherapy for 6 months after oophorectomy. The patient was alive with no evidence of disease 36 months after her oophorectomy. In the present report, we describe the case of a patient who underwent repeated resection for distant metastases after sigmoidectomy. These findings suggest that therapeutic strategies including surgical resection will be very important in the future.